
Yale Breast Cancer Drug Gets FDA Approval After 25 Years
A groundbreaking protein-degrading therapy developed at Yale just became the first of its kind approved by the FDA to treat an aggressive form of breast cancer. The once-daily pill offers new hope for thousands of women facing estrogen receptor-positive metastatic breast cancer.




